MRI confirms effectiveness of b-thalassemia treatment
British researchers have used T2* measures of cardiac iron loading to show the value of a new drug treatment for b-thalassemia, a genetic blood disorder. The laborious clinical trial involved transporting a mobile MRI system three times from London to the Mediterranean island of Sardinia.
British researchers have used T2* measures of cardiac iron loading to show the value of a new drug treatment for b-thalassemia, a genetic blood disorder. The laborious clinical trial involved transporting a mobile MRI system three times from London to the Mediterranean island of Sardinia.
Researchers found a 40% increase in T2* values, which represents a statistically significant drop in myocardial iron among beta-thalassemia patients who received a combined deferoxamine/deferiprone treatment for 12 months, according to Dr. Mark A. Tanner, a contrast MR researcher at Royal Brompton Hospital in London. T2* increases in the placebo-treated group were much smaller.
The results suggest that combined deferoxamine/deferiprone therapy will reduce the likelihood of cardiac iron loading and the threat of lethal complications, Tanner said.
"I suggest that combined therapy be considered in all patients who fail to achieve adequate iron load status on deferoxamine alone," he said.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
